DURECT Corporation - Drug delivery technologies treating chronic debilitating disease

Board of Directors

Corporate Policies/Governance

Driving Directions

Development Pipeline

Commercial Products

Research Programs

Business Development Approach

The SABER® Delivery System

ORADUR® Gel-Cap System

TRANSDUR® Transdermal Technology System

DURIN™ System

MICRODUR™ System

Localized Drug Delivery

Stock Information

Corporate Presentation

Earnings Estimate

Analyst Coverage

Financial Reports

Information Request

Benefits Overview

Attention Recruiters

About DURECT

Products

Business Development

Science & Technologies

Investor Relations

Careers

News

DURECT: Developing products to treat chronic debilitating disease and technologies that enable biotechnology products.

DURECT Featured Clinical Products

Latest News

ORADUR®

Indication:

Focus:

Chronic Pain

Remoxy®
A novel drug candidate to deter oxycodone abuse.

Learn more
View complete product pipeline

May 03, 2012
DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology

May 03, 2012
DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology

April 25, 2012
DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call

March 29, 2012
DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™

March 01, 2012
DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial Results

February 24, 2012
DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call

2010 Annual Report

2010 Annual Report

© 2000-2012 DURECT Corporation

Last updated: March 23, 2012
built@zoomedia.com

Contact